The short interest data are out for the March 31 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or break them. A single failed clinical trial can mean disaster for a stock. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.

The March 31 short interest data have been compared with the previous report, and short interest decreased across the board in these selected stocks.

Amgen Inc. (NASDAQ: AMGN) saw its short interest fall to 9.71 million shares from the previous level of 11.09 million. Shares closed most recently at $156.39, in a 52-week trading range of $130.09 to $181.81.

Biogen Inc. (NASDAQ: BIIB) had a short interest decrease to 2.52 million shares from the previous level of 2.88 million. Shares closed Monday at $265.19, within a 52-week range of $242.07 to $432.88.

Celgene Corp. (NASDAQ: CELG) short interest for this settlement date decreased to 9.99 million shares from the previous 12.22 million. Shares of Celgene closed most recently at $103.81, in a 52-week range of $92.98 to $140.72.

Gilead Sciences Inc. (NASDAQ: GILD) saw its short interest fall to 29.07 million shares from 31.72 million in the previous period. Shares closed Monday at $95.83, in a 52-week trading range of $81.89 to $123.37.

MannKind Corp. (NASDAQ: MNKD) saw its short interest decrease to 112.04 million shares. The previous reading was 120.54 million. Shares closed most recently at $1.52, in a 52-week trading range of $0.64 to $7.32.

Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) short interest decreased to 5.38 million, compared to the previous level of 5.93 million. Shares closed most recently at $147.88, in a 52-week range of $124.16 to $208.88.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.